Ari Shamiss
Co-Founder and Managing General Partner @ ALIVE Israel HealthTech Fund
Ari Shamiss is a Series C investor at ALIVE Israel HealthTech Fund focused on Health Care and Medical. Ari Shamiss is the CEO at Assuta Medical Centers. Ari Shamiss attended The Harvard Kennedy School.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Ari Shamiss invests in
Stages Ari Shamiss invests in
Countries Ari Shamiss invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Medical 1 (33%)
- Software 1 (33%)
- Biopharma 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series C 2 (67%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $55M / Series C / Mar 25, 2025 | ||
| Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $22M / Series B / Oct 27, 2022 | ||
| OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy.Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance.OncoHost was founded in 2017 and is headquartered in Binyamina, Israel. | $35M / Series C / May 10, 2022 |
Co-Investors
ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.
ALIVE Israel HealthTech Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ari Shamiss
Co-Founder and Managing General Partner
|
|||
Dudi Klein
Co-Founder and Managing Partner
|
|||
Dudi Klein
Co-Founder and Managing Partner
|
|||
Michel Habib
Co-Founder & Managing General Partner
|
|||
Prof. Rafael Beyar
Co-Founder and Managing General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ari Shamiss invest in?
Ari Shamiss invests primarily in Health Care, Medical and Software startups, most often at Series C and Series B stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ari Shamiss?
Public channels for Ari Shamiss include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ari Shamiss last invest?
The most recent investment recorded for Ari Shamiss closed in Mar 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
